Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 1999

View Archived Issues

FK-041: antibacterial potency in vitro and in vivo

Oral PEG-1000 formulation of 9-AC studied in phase I/pharmacokinetic solid tumor trial

Oxford GlycoSciences and Cellular Genomics form proteomics collaboration

StressGen launches new research initiative in allergy and asthma

Novel anti-HIV agents with 2-deoxystreptamine scaffold designed by Scriptgen

Neurogen patents potent and selective D4 antagonists

Inhibitors of cyclin-dependent kinases useful for neoplastic diseases and neuronal apoptosis

Selective brain GABA-A receptor ligands in the Neurogen pipeline

New agents for schizophrenia discovered at Warner-Lambert

Another group of histamine H3 receptor ligands patented by James Black

Mediolanum and Dompe introduce new agent for preventing DVT in Italy

Synercid profiled in JAC; U.K. product launch announced

Clinical trials to begin with Chiron anti-HIV compound

Start of phase II clinical trial of HMR-3480/ VX-740 as treatment for RA

Endorex sponsors phase I trial of new POH formulation

ODAC recommends approval of another new indication for Taxol

Capsaicin analogue with antihyperalgesic, antinociceptive effects under study at Novartis

FDA advisory committee unanimously recommends approval of UFT in metastatic colorectal cancer

Health Canada approves Aggrastat for management of unstable angina

Potent analgesic effects reported by Japanese investigators for TCPA

Pharmacia & Upjohn's Ellence receives FDA approval

Novel sulfone analogues of calcitriol are transcriptionally active, noncalcemic, antiproliferative

Ischemia-selective mechanism implicated in the antiarrhythmic activity of PAF antagonist

Positive preclinical results reported for Hemopure

Peptide Therapeutics proposes spin-out of drug discovery activities

Unique new selective FP receptor antagonist characterized by Alcon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...